Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TrivarX Limited ( (AU:TRI) ) has provided an update.
TrivarX Limited has exercised its option to acquire the Stabl-Im technology from Nucleics Pty Ltd, a novel brain imaging technology aimed at the early and safe detection of brain tumors. This acquisition, pending shareholder approval, represents a significant advancement in TrivarX’s diagnostic portfolio, potentially transforming brain cancer diagnostics by enabling earlier detection of tumor activity using stable isotope labeling detectable by MRI. The company plans to initiate a Phase 1 clinical trial in 2026, positioning itself at the forefront of precision imaging and expanding its influence in the oncology sector.
More about TrivarX Limited
TrivarX Limited is a mental health technology company focused on developing objective measures for the early detection and screening of mental health conditions. Founded in Australia, the company operates from offices in Perth and Minneapolis, and is listed on the Australian Securities Exchange and the OTCQB Venture Market.
YTD Price Performance: 31.25%
Average Trading Volume: 3,856,952
Technical Sentiment Signal: Sell
Current Market Cap: A$15.2M
For detailed information about TRI stock, go to TipRanks’ Stock Analysis page.